創科發展日漸成熟，癌症治療亦邁向科技化。中文大學成立「先進治療產品良好生產規範中心」下月正式啟用，是本港首個製造細胞及基因治療產品的科研機構，以基因改造細胞技術治療癌症、骨骼衰弱等，以往依賴海外完成的基因改造程序，有望改為本地研發，節省時間及成本；中心將與本地兩所醫院合作臨牀治療及研究。校長段崇智指，中心將積極推動生物醫學科技的研究，並歡迎其他院校加入。
CUHK has entered into a new partnership with the Hong Kong Science and Technology Parks Corporation (HKSTP) to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine and related biomedical technologies.
The Chinese University of Hong Kong (CUHK) and Hong Kong Science and Technology Parks Corporation (HKSTP), announce their partnership to build a world-class Good Manufacturing Practice (GMP) facility in Hong Kong to accelerate the development of life-saving cancer therapies, regenerative medicine, and related biomedical technologies.
The Chinese University of Hong Kong (CUHK) will commence clinical trials of Chimeric antigen receptor-T cell (CAR-T cell) therapy, with the first phase targeting patients with haematological malignancy. The plan is to increase the survival rate and prolong overall survival for these patients.
